Drug Profile
Duchenne muscular dystrophy cell therapy - CHUL Research Center
Latest Information Update: 30 Sep 2015
Price :
$50
*
At a glance
- Originator CHUL Research Center
- Class Cell therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Muscular dystrophies
Most Recent Events
- 29 Sep 2015 Clinical development is ongoing in Canada
- 06 Feb 2009 This programme is in active development in Canada
- 21 Jun 2005 Phase-I/II clinical trials in Muscular dystrophy in Canada (Injection)